Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent

Posted On Aug 16 2017 by

#epic pharma # Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200 June 09, 2015 08:00 ET | Source: Elite Pharmaceuticals, Inc. NORTHVALE, N.J. June 9, 2015 (GLOBE NEWSWIRE) — Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB:ELTP) announced today that it has entered into a sales and distribution licensing agreement with Epic Pharma LLC for ELI-200 (the “License”), an abuse-deterrent opioid utilizing Elite’s proprietary pharmacological abuse-deterrent technology. Epic will be responsible for sales and marketing of ELI-200, and Elite will be responsible for the manufacture of the product. Epic will pay Elite …


Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout #pharmaceutical #advertising

Posted On Aug 13 2017 by

#onyx pharma # Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout SOUTH SAN FRANCISCO, Calif. ( TheStreet ) — Every biotech CEO wants to say they bought an asset for X and sold it for 10X, yet few top executives manage to create value on this mammoth scale. Onyx Pharmaceuticals’ ( ONXX ) CEO Tony Coles just did it. The 10X is Amgen ( AMGN ) paying $10 billion in cash ($125 per share) to acquire Onyx. The deal, much discussed and analyzed since June, was finally announced Sunday night. But Amgen wouldn’t be buying Onyx …


TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program

Posted On Jul 31 2017 by

#transtech pharma # TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program March 05, 2015 04:03 PM Eastern Standard Time HIGH POINT, N.C.–( BUSINESS WIRE )–TransTech Pharma, LLC today announced a global licensing agreement granting Calithera Biosciences, Inc. exclusive world-wide rights to research, develop and commercialize TransTech’s portfolio of hexokinase II inhibitors. TransTech will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products. Hexokinase II is the first enzyme in the pathway that enables cancer cells to convert glucose …


Jazz moves into Ireland with Azur buy – RT – News #sun #pharma

Posted On Jul 26 2017 by

#azur pharma # Jazz moves into Ireland with Azur buy Thursday 19 January 2012 11.26 US company Jazz Pharmaceuticals has bought Irish firm Azur Pharma in a deal that creates a €1.5 billion specialty drug company headquartered in Dublin. Now named Jazz Pharmaceuticals plc, it has about 430 employees – 20 in Dublin – with offices also in Philadelphia and Palo Alto. One of the founders of Azur was former Elan executive Seamus Mulligan. Azur shareholders will own just over 20% of the new group, with Jazz shareholders owning the remainder of the combined firm. RELATED AUDIO VIDEO Azur Pharma …


Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent

Posted On Jul 24 2017 by

#epic pharma # Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200 June 09, 2015 08:00 ET | Source: Elite Pharmaceuticals, Inc. NORTHVALE, N.J. June 9, 2015 (GLOBE NEWSWIRE) — Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB:ELTP) announced today that it has entered into a sales and distribution licensing agreement with Epic Pharma LLC for ELI-200 (the “License”), an abuse-deterrent opioid utilizing Elite’s proprietary pharmacological abuse-deterrent technology. Epic will be responsible for sales and marketing of ELI-200, and Elite will be responsible for the manufacture of the product. Epic will pay Elite …


Novartis splits drugs business into two, pharma chief to leave #pharmaceutical #industry #companies

Posted On Jul 11 2017 by

#novartis pharma # Novartis splits drugs business into two, pharma chief to leave By John Miller and Ben Hirschler | ZURICH/LONDON ZURICH/LONDON (Reuters) – Novartis is splitting its pharmaceuticals division into two business units, one focused on cancer and the second on other drugs, while switching out its current pharma head in the second high-profile management reshuffle this year. David Epstein, the American head of Novartis Pharmaceuticals and a 27-year veteran with the group, will leave the company to “explore new challenges from the U.S.”, Novartis said. Epstein’s re-location to the United States implies he is not in the running …


Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent

Posted On Jul 10 2017 by

#epic pharma # Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200 June 09, 2015 08:00 ET | Source: Elite Pharmaceuticals, Inc. NORTHVALE, N.J. June 9, 2015 (GLOBE NEWSWIRE) — Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB:ELTP) announced today that it has entered into a sales and distribution licensing agreement with Epic Pharma LLC for ELI-200 (the “License”), an abuse-deterrent opioid utilizing Elite’s proprietary pharmacological abuse-deterrent technology. Epic will be responsible for sales and marketing of ELI-200, and Elite will be responsible for the manufacture of the product. Epic will pay Elite …


TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program

Posted On Jul 8 2017 by

#transtech pharma # TransTech Pharma and Calithera Biosciences Enter Into Worldwide Licensing Agreement for Hexokinase II Inhibitor Program March 05, 2015 04:03 PM Eastern Standard Time HIGH POINT, N.C.–( BUSINESS WIRE )–TransTech Pharma, LLC today announced a global licensing agreement granting Calithera Biosciences, Inc. exclusive world-wide rights to research, develop and commercialize TransTech’s portfolio of hexokinase II inhibitors. TransTech will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products. Hexokinase II is the first enzyme in the pathway that enables cancer cells to convert glucose …


Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout #top #pharma #companies

Posted On Jul 8 2017 by

#onyx pharma # Onyx Pharma CEO Turns $1 Billion Into $10 Billion With Amgen Takeout SOUTH SAN FRANCISCO, Calif. ( TheStreet ) — Every biotech CEO wants to say they bought an asset for X and sold it for 10X, yet few top executives manage to create value on this mammoth scale. Onyx Pharmaceuticals’ ( ONXX ) CEO Tony Coles just did it. The 10X is Amgen ( AMGN ) paying $10 billion in cash ($125 per share) to acquire Onyx. The deal, much discussed and analyzed since June, was finally announced Sunday night. But Amgen wouldn’t be buying Onyx …


Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent

Posted On May 31 2017 by

#epic pharma # Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200 June 09, 2015 08:00 ET | Source: Elite Pharmaceuticals, Inc. NORTHVALE, N.J. June 9, 2015 (GLOBE NEWSWIRE) — Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCQB:ELTP) announced today that it has entered into a sales and distribution licensing agreement with Epic Pharma LLC for ELI-200 (the “License”), an abuse-deterrent opioid utilizing Elite’s proprietary pharmacological abuse-deterrent technology. Epic will be responsible for sales and marketing of ELI-200, and Elite will be responsible for the manufacture of the product. Epic will pay Elite …